Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Overview
Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Companies Involved in Therapeutics Development
BeyondSpring Inc
Novartis AG
Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Drug Profiles
emricasan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate FADD for Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MBRI-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plibulin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Caspase 8, 9 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Dormant Products
Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Discontinued Products
Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Product Development Milestones
Featured News & Press Releases
Mar 25, 2019: BeyondSpring advancing patient targeting strategies for lead asset Plibulin
Mar 21, 2019: Cotus announces top-line results from ENCORE-NF phase 2b clinical trial in SH fibrosis
Mar 20, 2019: BeyondSpring to present clinical trial data on lead asset, Plibulin, at 2019 St. Gallen Intertiol Breast Cancer Conference
Mar 13, 2019: Cotus Late-breaker oral presentation at EASL meeting to detail results of ENCORE-PH Phase 2b clinical trial in patients with SH Cirrhosis and Severe Portal Hypertension
Mar 05, 2019: BeyondSpring presents new promising data in chemotherapy-induced neutropenia at 2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Feb 26, 2019: New data shows addition of BeyondSpring’s Plibulin reverses Neulasta’s potential immune-suppressive phenotype in treating chemotherapy-induced neutropenia
Feb 12, 2019: Cotus announces completion of enrollment in ENCORE-LF phase 2b clinical trial of Emricasan in patients with decompensated SH cirrhosis
Jan 28, 2019: Cotus Pharmaceuticals announces publications expanding on previously reported results from completed phase 2 FLD-SH, portal hypertension and liver cirrhosis clinical trials
Dec 27, 2018: BeyondSpring announces positive pre-NDA meeting with the U.S. FDA for its lead asset, Plibulin
Dec 21, 2018: United States patent and trademark office issues composition of matter patent with beyondspring’s lead asset Plibulin with protection to 2036
Dec 06, 2018: BeyondSpring announces phase 3 study 105 of its lead asset Plibulin for chemotherapy-induced neutropenia meets primary endpoint at interim alysis
Dec 05, 2018: Cotus Announces Results from ENCORE-PH Phase 2b Clinical Trial in SH Cirrhosis
Dec 04, 2018: Data for BeyondSpring’s lead asset, Plibulin, for chemotherapy-induced Neutropenia (CIN) prevention shows differentiated profile compared with G-CSF and adds additiol protection to G-CSF
Nov 27, 2018: Plibulin Newly Granted Patent Covering Method of Use in Prevention of Neutropenia
Nov 15, 2018: Study of plibulin, and nivolumab + ipilimumab in SCLC now open
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019


List of Tables


Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indications, H1 2019
Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Number of Products under Investigation by Universities/Institutes, H1 2019
Products under Investigation by Universities/Institutes, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by BeyondSpring Inc, H1 2019
Pipeline by Novartis AG, H1 2019
Dormant Products, H1 2019
Dormant Products, H1 2019 (Contd..1), H1 2019
Dormant Products, H1 2019 (Contd..2), H1 2019
Discontinued Products, H1 2019